<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04608838</url>
  </required_header>
  <id_info>
    <org_study_id>JTR-161-201</org_study_id>
    <nct_id>NCT04608838</nct_id>
  </id_info>
  <brief_title>A Randomized Placebo-controlled Multicenter Trial to Evaluate the Efficacy and Safety of JTR-161, Allogeneic Human Dental Pulp Stem Cell, in Patients With Acute Ischemic stRoke (J-REPAIR)</brief_title>
  <acronym>J-REPAIR</acronym>
  <official_title>An Exploratory, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety and Efficacy of JTR-161 in Patients With Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teijin Pharma Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teijin Pharma Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and efficacy of a single intravenous&#xD;
      administration of JTR-161 (allogeneic stem cell product derived from the dental pulp of&#xD;
      healthy adult humans) to patients with acute ischemic stroke.&#xD;
&#xD;
      This study is comprised of 3 cohorts and conducted in the order of Cohort 1, Cohort 2 and&#xD;
      Cohort 3.&#xD;
&#xD;
      Cohort 1 Arm-1: JTR-161, 1 × 10^8 cells/subject, 6 subjects Arm-2: Placebo, 2 subjects&#xD;
&#xD;
      The Data and Safety Monitoring Board (DSMB) and the Sponsor will decide whether Cohort 2 can&#xD;
      be initiated or not.&#xD;
&#xD;
      Cohort 2 Arm-1: JTR-161, 3 × 10^8 cells/subject, 6 subjects Arm-2: Placebo, 2 subjects&#xD;
&#xD;
      DSMB and the Sponsor will decide whether Cohort 3 can be initiated or not and the dose of&#xD;
      JTR-161 in Cohort 3.&#xD;
&#xD;
      Cohort 3 Arm-1: JTR-161, 1 × 10^8 cells/subject or 3 × 10^8 cells/subject, 30 subjects Arm-2:&#xD;
      Placebo, 30 subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 30, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Actual">February 15, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Some care providers who involved in the preparation or administration of dosing solutions are unblinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of patients who achieved Excellent outcome (modified Rankin Scale [mRS] ≤1 and National Institutes of Health Stroke Scale [NIHSS] ≤1 and Barthel Index [BI] ≥95) on Day 91 in Cohort 3.</measure>
    <time_frame>91 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who achieved mRS ≤ 1 or mRS ≤ 2</measure>
    <time_frame>366 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who achieved BI ≥ 95</measure>
    <time_frame>366 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who achieved NIHSS ≤ 1, who achieved improvement of ≥ 75%, and who achieved improvement of ≥ 10 points</measure>
    <time_frame>91 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in EQ-5D-5L scores</measure>
    <time_frame>366 days</time_frame>
    <description>The EuroQOL 5 dimension 5-level (EQ-5D-5L) consists of 2 parts: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS).&#xD;
The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: 1=&quot;no problems&quot;, 2=&quot;slight problems&quot;, 3=&quot;moderate problems&quot;, 4=&quot;severe problems&quot; and 5=&quot;extreme problems&quot;.&#xD;
The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who achieved excellent outcome (mRS ≤ 1, NIHSS ≤ 1, and BI ≥ 95)</measure>
    <time_frame>91 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who showed overall improvement (mRS ≤ 2, NIHSS improvement of ≥ 75%, and BI ≥ 95)</measure>
    <time_frame>91 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse events (signs and symptoms)</measure>
    <time_frame>366 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Laboratory tests (hematology, blood chemistry, blood coagulation test, urinalysis)</measure>
    <time_frame>366 days</time_frame>
    <description>Number of participants with clinical laboratory abnormalities for each parameter&#xD;
hematology Red blood cell count, Hemoglobin, Hematocrit, Platelet count, Leukocyte count, Leukocyte formula (neutrophils, lymphocytes, monocytes, eosinophils, basophils)&#xD;
blood chemistry Total protein, Albumin, Total bilirubin, Aspartate aminotransferase , Alanine aminotransferase, Alkaline phosphatase , Lactate dehydrogenase , γ-Glutamyltransferase, Blood urea nitrogen , Creatinine, Uric acid, Sodium, Potassium, Calcium, Chloride, Creatine kinase , C-reactive protein&#xD;
blood coagulation Prothrombin time (International normalized ratio) , Activated partial thromboplastin time&#xD;
urinalysis Urine Protein, Urine Glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Vital signs (blood pressure [systolic/diastolic], pulse rate, body temperature)</measure>
    <time_frame>366 days</time_frame>
    <description>Number of participants of the vital signs abnormalities for each parameter: blood pressure (mmHg), pulse rate (bpm) and body temperature (℃).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Oxygen saturation (SpO2)</measure>
    <time_frame>366 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in findings of imaging examination by Magnetic Resonance Imaging (MRI) or Computed Tomography (CT).</measure>
    <time_frame>31 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>JTR-161</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>JTR-161</intervention_name>
    <description>JTR-161 (1 or 3 × 10^8 cells/subject) will be suspended and administered in an intravenously infusion.</description>
    <arm_group_label>JTR-161</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be suspended and administered in an intravenously infusion.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who have ischemic strokes in the anterior circulation&#xD;
&#xD;
          -  Patients whose mRS is 0 or 1 prior to the onset of ischemic stroke&#xD;
&#xD;
          -  Patients whose NIHSS score of ≥5 to ≤20 at screening&#xD;
&#xD;
          -  Patients who can be administered dosing solutions within 48 h of stroke onset&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have new ischemic lesion in the cerebellum or brainstem&#xD;
&#xD;
          -  Patients whose consciousness level drops severely&#xD;
&#xD;
          -  Patients whose infarct area is widespread&#xD;
&#xD;
          -  Patients who have a clinically significant hemorrhagic transformation&#xD;
&#xD;
          -  Patients who had seizures after onset of ischemic stroke&#xD;
&#xD;
          -  Patients who have medical history of a neurological event such as stroke or clinically&#xD;
             significant head trauma within 180 days prior to giving informed consent&#xD;
&#xD;
          -  Patients who have poor blood pressure control&#xD;
&#xD;
          -  Patients who have poor glycaemic control&#xD;
&#xD;
          -  Patients who have one of the following complications&#xD;
&#xD;
               1. Severe liver dysfunction&#xD;
&#xD;
               2. Severe kidney dysfunction&#xD;
&#xD;
               3. Severe heart failure&#xD;
&#xD;
               4. Severe pulmonary dysfunction&#xD;
&#xD;
          -  Patients who have severe infections&#xD;
&#xD;
          -  Patients who have any neurological disorder affecting informed consent or study&#xD;
             assessments&#xD;
&#xD;
          -  Patients who have the malignant tumor, or medical history of malignant tumor within 2&#xD;
             years prior to the onset of ischemic stroke&#xD;
&#xD;
          -  Patients who have a contraindication for MRI&#xD;
&#xD;
          -  Patients who have thrombocytopenia&#xD;
&#xD;
          -  Patients who have medical history of allergy to products derived from human tissues,&#xD;
             bovine or porcine&#xD;
&#xD;
          -  Patients who have medical history of allergy to streptomycin&#xD;
&#xD;
          -  Patients who have undergone splenectomy in the past&#xD;
&#xD;
          -  Patients who have a possibility of transient ischemic attack&#xD;
&#xD;
          -  Patients who are scheduled to undergo revascularization (carotid endarterectomy, stent&#xD;
             placement etc.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nippon Medical School Hospital</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 8, 2020</study_first_submitted>
  <study_first_submitted_qc>October 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2020</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Ischemic Stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

